
Deverra Therapeutics: Pioneering allogeneic cellular immunotherapies in biotechnology.
Deverra Therapeutics, founded with the mission to develop cost-effective and accessible allogeneic cellular immunotherapies, focuses on creating universal donor cell therapies. Utilizing a platform technology based on sustainable, healthy donor umbilical cord blood, the company aims to revolutionize the biotechnology sector by offering innovative treatments for various diseases. Their market focus includes providing these advanced therapies to a broad patient base, ensuring that cutting-edge medical solutions are within reach for all.
Notable individuals affiliated with Deverra Therapeutics include experts in biotechnology and cellular therapy, though specific names are not provided. The company has achieved significant milestones, including launching an equity crowdfunding campaign on StartEngine to further their research and development efforts. Deverra's impact lies in its potential to transform the landscape of cellular immunotherapies, making advanced medical treatments more universally available and affordable.

ImmuneBridge
immunebridge.com

Celularity
celularity.com

Cell BioEngines
cellbioengines.com

Platelet BioGenesis

Cellevolve Bio
cellevolve.com

Verve Therapeutics
vervetx.com

Appia Bio
appiabio.com

Alloplex Biotherapeutics

Allogene Therapeutics
allogene.com

Longeveron
longeveron.com

Kyverna Therapeutics

CERo Therapeutics
cero.bio

Cellular Approaches

Garuda Therapeutics
garudatx.com

Medeor Therapeutics
medeortx.com
Companies similar to Deverra Therapeutics include ImmuneBridge, Celularity, Cell BioEngines and Platelet BioGenesis.
Deverra Therapeutics was founded in 2020.
Deverra Therapeutics' headquarters is located in Seattle, WA, US.
Deverra Therapeutics' most recent funding round was for $3.5M (USD) in September 2023.
As of Sep 11, 2023, Deverra Therapeutics has raised a total of $3.6M (USD).
Deverra Therapeutics has 11 employees as of Feb 5, 2024.